Dynacure, a Strasbourge, France-based biotechnology company developing new treatments for patients affected by serious orphan disorders, completed a €47m financing round (~US$55m).
The round was led by Andera Partners (formerly Edmond de Rothschild Investment Partners), joined by Pontifax, Bpifrance, Kurma Partners and IdInvest Partners.
The company intends to use the funds to advance its lead antisense oligonucleotide candidate for centronuclear myopathy (CNM), and additional preclinical research programs forotherorphan disorders into clinical development.
Led by Stephane van Rooijen, chief executive officer, Dynacure develops new treatments for patients suffering from serious orphan disorders. The company is advancing Dyn101, an antisense oligonucleotide therapy in development for the rare and often fatal muscle disease centronuclear myopathy (CNM). It is being developed in collaboration with Ionis Pharmaceuticals, an RNA-targeted drug discovery, development and commercialization company.
Dynacure was founded by Kurma Partners, SATT Conectus and Ionis Pharmaceuticals in 2016, based on foundational research conducted at the Institute of Genetic and Molecular and Cellular Biology (IGBMC) in Strasbourg; Bpifrance joined as an early investor in 2017.